PE20190517A1 - Preparacion farmaceutica antienvejecimiento - Google Patents

Preparacion farmaceutica antienvejecimiento

Info

Publication number
PE20190517A1
PE20190517A1 PE2019000361A PE2019000361A PE20190517A1 PE 20190517 A1 PE20190517 A1 PE 20190517A1 PE 2019000361 A PE2019000361 A PE 2019000361A PE 2019000361 A PE2019000361 A PE 2019000361A PE 20190517 A1 PE20190517 A1 PE 20190517A1
Authority
PE
Peru
Prior art keywords
liquid
cellular constituents
container
aging
pharmaceutical preparation
Prior art date
Application number
PE2019000361A
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/001888 external-priority patent/WO2017080669A1/en
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of PE20190517A1 publication Critical patent/PE20190517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)

Abstract

Se refiere a un metodo de preparacion de una composicion antienvejecimiento, el cual comprende: proporcionar un liquido recolectado a partir de un organismo cuyo liquido comprende constituyentes celulares de la sangre, poner en contacto el liquido con un recipiente o medio de contencion. Dicho metodo de preparacion tambien comprende incubar el liquido en el recipiente y opcionalmente eliminar los constituyentes celulares del liquido tras la incubacion. Dicho liquido comprende exosomas que se concentran y opcionalmente eliminar los constituyentes celulares del liquido luego de la concentracion o aislar los exosomas. El metodo tambien comprende la etapa de evitar la incubacion del liquido y la eliminacion de los constituyentes celulares del liquido en contacto con el recipiente o los medios de contencion
PE2019000361A 2016-08-17 2017-05-12 Preparacion farmaceutica antienvejecimiento PE20190517A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001807 2016-08-17
PCT/EP2016/001888 WO2017080669A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders
PCT/EP2016/001887 WO2017080668A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders

Publications (1)

Publication Number Publication Date
PE20190517A1 true PE20190517A1 (es) 2019-04-10

Family

ID=61196401

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000304A PE20190627A1 (es) 2016-08-17 2017-05-11 Preparacion farmaceutica antienvejecimiento
PE2019000361A PE20190517A1 (es) 2016-08-17 2017-05-12 Preparacion farmaceutica antienvejecimiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019000304A PE20190627A1 (es) 2016-08-17 2017-05-11 Preparacion farmaceutica antienvejecimiento

Country Status (21)

Country Link
US (3) US20190290689A1 (es)
EP (4) EP3695845A1 (es)
JP (2) JP2019528281A (es)
KR (2) KR20190049690A (es)
CN (2) CN108348548A (es)
AU (2) AU2017313163B2 (es)
BR (2) BR112019002080A2 (es)
CA (2) CA3033045A1 (es)
CL (2) CL2019000419A1 (es)
CO (2) CO2019001232A2 (es)
CR (2) CR20190139A (es)
EA (2) EA201890841A1 (es)
HK (3) HK1255619A1 (es)
IL (2) IL259007B1 (es)
MA (2) MA42963A (es)
MX (2) MX2019001948A (es)
PE (2) PE20190627A1 (es)
PH (2) PH12019550017A1 (es)
SG (2) SG11201900866YA (es)
TW (2) TW201806605A (es)
WO (3) WO2018033226A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528281A (ja) * 2016-08-17 2019-10-10 オアトゲン アクチエンゲゼルシャフトＯＲＴＨＯＧＥＮ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 加齢防止製剤
CN108841784A (zh) * 2018-07-17 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种含黄芪甲苷的髓核细胞抗衰老抗凋亡培养基
EP3613424A1 (en) 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
SG11202105579VA (en) * 2018-12-27 2021-07-29 Suntory Holdings Ltd Agent for inhibiting reduction in decomposition of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafine composite, and screening method for substance having elastin-elafine composite formation inhibitory effect
RU2695264C1 (ru) * 2018-12-27 2019-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) Способ прогнозирования ускоренного старения организма женщин, основанный на клинических данных о состоянии репродуктивной функции

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005262319A1 (en) * 2004-07-01 2006-01-19 Orthogen Ag Immunosuppressive exosomes
DE102006005016A1 (de) * 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
WO2012076193A1 (de) * 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
EP3563859B1 (en) * 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN103767985A (zh) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
KR101784050B1 (ko) * 2014-12-23 2017-10-10 영남대학교 산학협력단 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물
CN105477016A (zh) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 人间充质干细胞来源的外泌体在抗组织纤维化及瘢痕形成中的应用
TW201722443A (zh) * 2015-11-13 2017-07-01 奧爾托金公司 對老化相關病症有效之醫藥製劑
CN105505854B (zh) * 2016-01-14 2019-07-12 上海市第六人民医院 来源于人尿液细胞的外泌体的获取方法与应用
CN105582576B (zh) * 2016-02-23 2018-08-17 武汉大复生物科技有限公司 提高内皮祖细胞外泌体释放并促进骨缺损修复的生物材料、制备方法及用途
JP2019528281A (ja) * 2016-08-17 2019-10-10 オアトゲン アクチエンゲゼルシャフトＯＲＴＨＯＧＥＮ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 加齢防止製剤

Also Published As

Publication number Publication date
BR112019002080A2 (pt) 2019-05-14
HK1259143A1 (zh) 2019-11-29
IL259006A (en) 2018-07-31
CA3033045A1 (en) 2018-02-22
SG11201900866YA (en) 2019-02-27
HK1258712A1 (zh) 2019-11-15
JP2019529357A (ja) 2019-10-17
EA201890841A1 (ru) 2018-09-28
BR112019002982A2 (pt) 2019-05-14
EA201890840A1 (ru) 2018-09-28
PE20190627A1 (es) 2019-04-26
EP3352769A1 (en) 2018-08-01
WO2018033226A1 (en) 2018-02-22
KR20190049690A (ko) 2019-05-09
US20210290671A1 (en) 2021-09-23
CN108348548A (zh) 2018-07-31
US20190231816A1 (en) 2019-08-01
CL2019000419A1 (es) 2019-07-05
MX2019001948A (es) 2019-05-15
AU2017313164B2 (en) 2019-01-03
IL259007A (en) 2018-07-31
SG11201901085RA (en) 2019-03-28
AU2017313163B2 (en) 2019-01-03
PH12019550022A1 (en) 2019-12-02
CR20190091A (es) 2019-05-07
WO2018033249A1 (en) 2018-02-22
JP2019528281A (ja) 2019-10-10
CO2019001265A2 (es) 2019-02-28
WO2018033227A1 (en) 2018-02-22
CL2019000420A1 (es) 2019-07-05
PH12019550017A1 (en) 2019-11-04
CO2019001232A2 (es) 2019-02-28
CR20190139A (es) 2019-06-03
CN108348549A (zh) 2018-07-31
HK1255619A1 (zh) 2019-08-23
WO2018033227A8 (en) 2019-01-24
TW201806605A (zh) 2018-03-01
AU2017313164A1 (en) 2018-05-10
AU2017313163A1 (en) 2018-05-10
EP3763377A1 (en) 2021-01-13
EP3352770A1 (en) 2018-08-01
EP3695845A1 (en) 2020-08-19
CA3033899A1 (en) 2018-02-22
MX2019001949A (es) 2019-05-15
MA42964A (fr) 2018-08-01
MA42963A (fr) 2018-08-01
KR20190046793A (ko) 2019-05-07
IL259007B1 (en) 2024-03-01
TW201806606A (zh) 2018-03-01
US20190290689A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
CL2016002105A1 (es) Método in vitro para determinar un pronóstico pobre en un paciente que tiene melanoma que comprende: (a) detectar el nivel de expresión de un ligando similar a delta 3 (dll3) en una muestra, donde la detección comprende poner en contacto la muestra con un anticuerpo anti-dll3.
AR080478A1 (es) Metodos para extraer y aislar constituyentes de un material ceculosico
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
ES2650950T3 (es) Un método para filtrar una muestra biológica
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
AR089900A1 (es) Composiciones y metodos para la recuperacion y/o eliminacion de reactivos de medios porosos
MX2017001979A (es) Metodo y aparato in vitro para analizar el comportamiento de sustancias en ambiente fisiologico simulado.
CL2014001150A1 (es) Sistema y metodo donde el sistema particularmente es un dispositivo movil, para la determinacion de la concentracion de solutos en una muestra liquida coloreada, el cual se basa en la obtencion de imagenes de la muestra y de patrones de concentracion conocidos del soluto, y la determinacion de la concentracion de la muestra sobre la base del procesamiento de esas imagenes y los valores de color que las mismas proporcionan
CO2017003251A2 (es) Método para autentificación de líquido por detección de derivados de flavonoide
FR2986071B1 (fr) Procede pour pronostiquer,in vitro, dans un echantillon sanguin, la probabilite pour un patient d'evoluer vers une dengue severe
EA201692182A1 (ru) Способ изготовления технологического устройства и технологическое устройство
PE20141723A1 (es) Metodo para monitoreo, diagnostico y/o pronostico de trastornos relacionados con hipoxia utilizando nfat5
IT201600069927A1 (it) Metodo per la diagnosi in vitro di carcinoma tiroideo.
MX2017002453A (es) Neprilisina como marcador pronostico de insuficiencia cardiaca.
UA103347U (ru) Способ выделения метацеркарии трематода paracoenogonimus ovatus
DK3638109T3 (da) Fremgangsmåde til bestemmelse af koncentrationen af en analyt i fuldblod
AR107115A1 (es) Una película plástica pintable y su proceso de elaboración
UA117286C2 (uk) 2-гетарил-2-(n-r-піролідин-2-іліден)ацетонітрили та спосіб їх отримання (варіанти)
UA114636U (xx) Спосіб виявлення глікопротеїнових комплексів еритробластного острівця червоного кісткового мозку на напівтонких зрізах
MX369011B (es) Agentes moleculares marcados para representar por una imagen el anti-portador de cistina/glutamato.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal